Gilgamesh Pharmaceuticals is a pharmaceutical company that is developing psychedelic and related drugs as medicines. It is a "discovery stage" company and is focused on developing new chemical entities. Its drug candidates include the ketamine-related NMDA receptor antagonist blixeprodil (GM-1020; (R)-4-fluorodeschloroketamine or (R)-4-FDCK), the dimethyltryptamine (DMT)-related serotonergic psychedelic bretisilocin (GM-2505; 5-fluoro-N-methyl-N-ethyltryptamine or 5F-MET), the noribogaine-related κ-opioid receptor agonist GM-3009, and the non-hallucinogenic psychoplastogen GM-5022. Another potential candidate is GM-2040, a putatively non-hallucinogenic serotonin 5-HT2A receptor agonist. The company was co-founded by Jonathan Sporn, Jeff Witkin, Dalibor Sames, Andrew Kruegel, and Mike Cunningham. Cunningham is a research scientist at Gilgamesh. Sames, Kruegel, and Cunningham have worked together at Sames's lab at Columbia University. In May 2024, AbbVie made an optional deal with Gilgamesh Pharmaceuticals to pay $65 million upright for rights to novel non-hallucinogenic psychoplastogens. It also agreed to pay up to $1.95 billion for a series of psychoplastogens.
Gilgamesh Pharmaceutical has received investment from 1 venture capital firm.
Gilgamesh Pharmaceuticals is a pharmaceutical company that is developing psychedelic and related drugs as medicines.
Gilgamesh Pharmaceutical has received investment from James Beshara Fund. These venture capital firms and investors provide both capital and strategic support.
Gilgamesh Pharmaceutical operates in the Biotech sector. Gilgamesh Pharmaceuticals is a pharmaceutical company that is developing psychedelic and related drugs as medicines.
